Sandborn W.J. (1998) Azathioprine: State of the art in inflammatory bowel disease. Scand J Gastroenterol 33(SUPPL. 225):92-99.
Louis E., Belaiche J. (1999) Treatment of inflammatory bowel disease with azathioprine: How to use it in 1999. Acta Gastroenterol Belg 62:437-439.
Krynetski E.Y., Tai H.L., Yates C.R., Fessing M.Y., Loen-Nechen T., Schuetz J.D. (1996) Genetic polymorphism of thiopurine S-methyltransferase: Clinical importance and molecular mechanisms. Pharmacogenetics 6:279-290.
Lennard L. (1998) Clinical implications of thiopurine methyltransferase-optimization of drug dosage and potential drug interactions. Therapeutic Drug Monitor 20:527-531.
Szumlanski C.I., Weinshilboum R.M. (1995) Sulphasalazine inhibition of thiopurine methyltransferase: Possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Pharmacol 39:456-458.
Pearson D.C., May G.R., Fick G.H., Sutherland L.R. (1995) Azathioprine and 6-mercaptopurine in Crohn's disease: A meta-analysis. Ann Intern Med 122:132-142.
Sandborn W.J., Tremaine W.J., Wolf D.C., Targan S.R., Sninsky C.A., Sutherland L.S. (1999) Lack of intravenous administration on time to respond to azathioprine for steroidtreated Crohn's disease. Gastroenterology 117:527-535.
Present D.H., Korelitz B.I., Wisch N., Glass J.L., Sachar D.B., Pasternack B.S. (1980) Treatment of Crohn's disease with 6-mercaptopurine: A long-term, randomized, double-blind study. N Engl J Meal 302:981-987.
Blondel-Kucharski F., Chircop C., Marquis P., Colombel J.F., Gendre J.P. (1999) Qualité de vie au cours de la maladie de Crohn: Étude prospective longitudinale de 231 patients. Gastroenterol Clín Biol 23.
Markowitz J., Grancher K., Kohn N., Lesser M., Daum F. (2000) A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119:895-902.
Korelitz B., Hanauer S., Rutgeerts P., Present D., Peppercorn M. (1998) Postoperative prophylaxis with 6MP, 5-ASA, or placebo in Crohn's disease: O 2 year multicenter trial. Gastroenterology 113.
D'Haens G.R., Geboes K., Ponette E., Pennincks F., Rutgeerts P. (1997) Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 112:1475-1481.
Van Dullemen H.M., Van Deventer S.H.J., Hommes D.W., Bijl H.A., Jansen J., Tytgat G.N. (1995) Treatment of Crohn's disease with anti-tumar necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129-135.
Arsenau K.O., Gross M.P., Bickson S.J., McCone J., Valle E., Cominelli F. (2000) Preliminary clinical experience with infliximab in the treatment of refractory and fistulizing Crohn's disease (CD). Gastroenterology 118.
McCabe R.P., Schwartz R.M., Bedeau V., Tatarek N., Weinberg D.I. (2000) Treatment of Crohn's disease with infliximab: An initial community practice experience. Gastroenterology 118.
Cohen R.D., Tsang J.F., Hanauer S. (2000) Infliximab in Crohn's disease: First anniversary clinical experience. Am J Gastroenterol 95:3469-3477.
Raedler A., Peters I., Schreiber S. (1997) Treatment with azathioprine and budesonide prevents reoccurence of ileocolonic stenosis after endoscopic dilatation in Crohn's disease. Gastroenterology 112.
Barbe L., Marteau Ph., Lemann M., Bouhnik Y., Allez M., Goffin B. (1998) Dose raising of azathioprine beyond 2.5 mg/kg/day in Crohn's disease patients who fail to improve with a standard dose. Gastroenterology 114.
Colonna T., Korelitz B.I. (1994) The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol 89:362-366.
Belaiche J., Desager J.P., Horsmans Y., Louis E. (2001) Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn's disease. Scand J Gastroenterol 36:71-76.
Cattan S., Lemann M., Thuillier F., Bengoufa D., Rabian C., Ngo Y. (1998) Dosage de la 6-mercaptopurine et étude des souspopulations lymphocytaires sanguines au cours du traitement par azathioprine dans la maladie de Crohn. Gastroenterol Clin Biol 22:160-167.
Lillemans J.S., Lennard L. (1994) Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukemia. Lancet 343:1188-1190.
Schutz E., Gummert J., Amstrong V.W., Mohr F.W., Oellerich M. (1996) Azathioprine pharmacogenetics: The relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation. Eur J Clin Chem Clin Biochem 34:199-205.
Cuffari C., Théort Y., Latour S., Seidman G. (1996) 6-Mercaptopurine metabolism in Crohn's disease: Correlation with efficacy and toxicity. Gut 39:401-406.
Cuffari C., Picco M., Hunt S., Bayless T. (1999) Azathioprine metabolite levels predict clinical responsiveness to therapy in IBD. Gastroenterology 116.
Dubinski M.C., Lamothe S., Yang H.Y., Targan S.R., Sinnett D., Théort Y. (2000) Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118:705-713.
Lémann M., Bonhomme P., Bitoun A., Messing B., Modigliani R., Rambaud J.C. (1990) Traitement de la maladie de Crohn par l'azathioprine ou la 6-mercaptopurine: Étude rétrospective chez 126 malades. Gastroenterol Clin Biol 14:548-554.
Sandborn W.J., Van Os E.C., Zins B.J., Tremaine W.J., Mays D.C., Lipsky J.J. (1995) An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 109:1808-1817.
Louis E., Dupont P., Depauw A., Croes F., Demolin G., Belaiche J. (1998) Rapide anti-inflammatory effect of high dose azathioprine in inflammatory bowel disease: An in vitro study. Gastroenterology 114.
Bouhnik Y., Lémann M., Mary J.Y., Scemama G., Tai R., Matuchanski C. (1996) Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 347:215-219.
Kim P.S., Zlatanic J., Korelitz B.I., Gleim G.W. (1999) Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. Am J Gastroenterol 94:3254-3257.
Lémann M., Bouhnik Y., Kmieciak L.E., Corguille M., Bonnet J., Goffin B. (1997) Treatment of Crohn's disease (CD) with 6-mercaptopurine (6MP) in patients intolerant to azathioprine (AZA). Gastroenterology 112.
Connel W.R., Kamm M.A., Ritchie J.K., Lennard-Jones J.E. (1993) Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 Years of experience. Gut 34:1081-1085.
Colombel J.F., Ferrari N., Debuysere H., Marteau P., Gendre J.P., Bonaz B. (2000) Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118:1025-1030.
Evans W.E., Homer M., Chu Y.Q., Kalwinski D., Roberts W.M. (1991) Altered mercaptopurine metabolism toxic effects, and dosage requirement in a thiopurine methyl-transferase deficient child with acute lymphocytic leukemia. J Pediatr 119:985-989.
Present D.H., Meltzer S.J., Krumholtz M.P., Wolke A., Korelitz B.I. (1989) 6-Mercaptopurine in the management of inflammatory bowel disease: Short and long-term toxicity. Ann Intern Med 111:641-649.
Connell W.R., Kamm Ma., Dickson M., Balkwill A.M., Ritchie J.K., Lennard-Jonnes J.E. (1994) Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 343:1249-1252.
Loftus E.V., Tremaine W.J., Habermann T.M., Harmsen W.S., Zinsn A.R., Sandborn W.J. (2000) Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 95:2308-2312.
Lewis J.D., Schwartz S., Lichtenstein G.R. (2000) Azathioprine for maintenance of remission in Crohn's disease: Benefits outweight the risk of lymphoma. Gastroenterology 118:1018-1024.
Korelitz B.I., Mirsky F.J., Fleisher M.R., Warman J.I., Gleim G.W. (1999) Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 94:3248-3253.
Alstead E.M., Ritchie J.K., Lennard-Jonnes J.E., Farthing M.J.C., Clark M.L. (1990) Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 90:443-446.
Francella A., Dayan A., Rubin P., Chapman M., Present D. (1996) 6-Mercaptopurine is safe therapy for child bearing patients with inflammatory bowel disease: A case controlled study. Gastroenterology 110.
Rajapakse R.O., Korelitz B.I., Zlatanic J., Baiocco P.J., Gleim G.W. (2000) Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 95:684-688.
Seidman E.G. (2000) 6-Mercaptopurine in maintaining remission in Crohn's disease: An old friend becomes a new hero. Gastroenterology 119:1158-1160.
